Litigation Details for Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Docket	1:16-cv-00375	Date Filed	2016-05-20
Court	District Court, D. Delaware	Date Terminated	2016-07-27
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,039,009; 8,058,291; 8,168,209; 8,173,708; 8,283,379; 8,293,794; 8,329,752; 8,338,485; 8,338,486; 8,362,085; 8,580,858; 8,598,233
Link to Docket	External link to docket

Details for Forest Laboratories, LLC v. Accord Healthcare, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-05-20				External link to document
2016-05-20	3		Received Notice: 5/6/2016. Date of Expiration of Patent: 8,039,009 - September 24, 2029, 8,329,752 - May 22, … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2016 27 July 2016 1:16-cv-00375 830 Patent None District Court, D. Delaware	External link to document
2016-05-20	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,009 B2; 8,058,291 B2; 8,168,209…2016 27 July 2016 1:16-cv-00375 830 Patent None District Court, D. Delaware	External link to document

Forest Laboratories v. Accord Healthcare: Viibryd Patent Litigation Summary, Case No. 1:16-cv-00375

Last updated: August 10, 2026

Forest Laboratories, LLC sued Accord Healthcare, Inc. in the U.S. District Court for the District of Delaware after Accord filed an abbreviated new drug application seeking approval for a generic version of Viibryd, the branded antidepressant containing vilazodone hydrochloride. The case was an ANDA-based patent action under the Hatch-Waxman Act. Forest asserted Viibryd patents listed in the FDA Orange Book and sought to delay FDA approval of Accord's generic product.

The public docket reflects a patent dispute resolved without a reported trial or Federal Circuit merits decision. The case did not produce a published ruling invalidating the asserted Viibryd patents or finding them infringed after trial. Its commercial significance was the potential timing of generic vilazodone entry and the remaining patent barriers surrounding Viibryd.

What drug and patents were involved in Forest Laboratories v. Accord?

The case involved Viibryd, whose active ingredient is vilazodone hydrochloride. Viibryd is an orally administered antidepressant approved by the FDA for major depressive disorder.

Forest's Viibryd patent estate included patents directed to the active pharmaceutical compound and methods of using vilazodone. The patents most closely associated with the 2016 ANDA litigation included:

Patent	General subject matter	Relevance to Viibryd
U.S. Patent No. 7,834,020	Vilazodone compound and related pharmaceutical subject matter	Core compound protection
U.S. Patent No. 8,236,800	Vilazodone treatment and pharmaceutical use claims	Later-expiring method-of-use protection
U.S. Patent No. 8,673,921	Later-developed vilazodone-related subject matter	Potential secondary protection

The precise claims asserted against Accord depended on the contents of Accord's ANDA and the Paragraph IV certification provided to Forest. ANDA litigation commonly includes claims that the generic product would infringe composition, formulation, or method-of-treatment claims before FDA approval.

The principal commercial patent dates were materially different. The earliest core patent protection was scheduled to expire in 2022, while later patent protection could extend into the late 2020s or beyond, subject to patent-term adjustment, pediatric exclusivity, claim scope, validity, and Orange Book listing status.

What was the legal basis for the Accord Healthcare lawsuit?

Forest filed the action under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA containing a Paragraph IV certification as a technical act of patent infringement. Accord's ANDA filing allegedly represented that one or more Viibryd patents were invalid, unenforceable, or would not be infringed by Accord's proposed generic product.

Forest's complaint sought:

• A declaration that the asserted patents were valid and enforceable.
• A declaration that Accord's proposed product would infringe.
• An injunction preventing FDA approval before patent expiration.
• The statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii).
• Costs, attorneys' fees, and other relief available under the Hatch-Waxman framework.

An ANDA action does not establish that a generic product has entered the market. It tests whether approval and commercial launch should be delayed based on the listed patents.

What was the Orange Book status of Viibryd?

Viibryd was approved by the FDA in 2011. Its original five-year new chemical entity exclusivity period expired in 2016. FDA exclusivity and patent protection were separate:

Protection	Approximate status
FDA approval	2011
Five-year NCE exclusivity	Expired in 2016
Core patent protection	Extended beyond 2016, principally into 2022
Later method or secondary patents	Potentially extended into the late 2020s or later
Pediatric exclusivity	Depended on completion of FDA-requested pediatric obligations and the applicable Orange Book entry

The expiration of NCE exclusivity allowed ANDA applicants to file Paragraph IV challenges. It did not authorize immediate generic marketing because the Orange Book-listed patents remained enforceable.

The operative Orange Book analysis must distinguish between patents listed against the original Viibryd tablets and patents later added for formulations, strengths, labeling, or methods of treatment. A patent's inclusion in the Orange Book does not by itself establish infringement or validity.

When could Accord's generic Viibryd launch?

Accord's launch timing depended on four variables:

1. The validity and scope of the asserted patents.
2. The date of any settlement or dismissal.
3. The expiration of the Hatch-Waxman 30-month stay.
4. Accord's eligibility for 180-day first-applicant exclusivity.

The 30-month stay generally begins when the NDA holder receives notice of a Paragraph IV certification and files suit within the statutory period. The stay delays FDA approval, subject to statutory exceptions and court orders. A settlement can establish an agreed launch date that is earlier than the latest asserted patent expiration.

The docket does not establish an adjudicated right for Accord to launch before the listed patent expirations. Nor does the case itself establish that Accord was the first Paragraph IV filer. Generic launch therefore depended on the broader Viibryd litigation and any confidential or partially disclosed settlement terms.

Did Forest win the case against Accord?

The case did not result in a reported merits judgment against Accord. Public docket materials indicate that the action was resolved through dismissal or settlement rather than a completed bench trial.

The practical result was different from a patent invalidity judgment:

• Forest did not receive a published ruling confirming every asserted patent claim.
• Accord did not obtain a published decision invalidating the Viibryd patents.
• The docket did not create a generally applicable ruling binding other ANDA applicants.
• Any agreed launch date or commercial restriction was specific to the parties and settlement terms.

In Hatch-Waxman litigation, dismissal after settlement is common. It can preserve the branded company's patent position while giving the generic company a defined future launch path.

What patent litigation affected Viibryd beyond Accord?

Forest brought parallel Viibryd cases against other ANDA applicants. These cases created a portfolio-level risk rather than a single-defendant risk. A branded company can settle with one generic manufacturer while continuing to litigate against others.

The relevant competitive questions were:

• Whether multiple applicants challenged the same compound patent.
• Whether any applicant asserted a noninfringement position based on a different formulation.
• Whether later method-of-use patents covered the generic label.
• Whether a skinny-label strategy could avoid infringement of treatment claims.
• Whether a first-filer settlement controlled or affected later generic entry.

A Paragraph IV settlement with Accord did not necessarily clear the entire generic field. Other applicants could remain subject to separate litigation, separate settlement dates, or different patent certifications.

How strong was Forest's Viibryd patent estate?

Forest's estate had moderate commercial strength because it combined early core protection with later secondary patents. Its principal strengths were:

• A compound patent tied directly to vilazodone.
• FDA-listed patents capable of triggering the 30-month stay.
• Later method-of-use or formulation claims that could extend protection beyond the earliest compound expiration.
• Multiple ANDA suits that increased settlement leverage.

Its weaknesses were equally important:

• The core patent was scheduled to expire relatively soon after the 2016 lawsuits.
• Vilazodone is a small-molecule drug, so generic substitution did not present biosimilar-style manufacturing barriers.
• Paragraph IV litigation exposed the patents to validity challenges.
• Method-of-use claims can be vulnerable to skinny-label strategies.
• A settlement could establish an earlier generic launch date than the outer patent term.

The estate was therefore stronger as a litigation and timing asset than as a permanent barrier to generic competition.

Did biosimilar risk apply to Viibryd?

No. Viibryd is a small-molecule drug, not a biologic. Accord's product would have proceeded through the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not through the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution, not biosimilar interchangeability. Manufacturing risk centered on chemical synthesis, solid-state form, release characteristics, analytical equivalence, and compliance with the FDA's ANDA requirements.

What revenue exposure did the litigation create?

The litigation exposed Forest's Viibryd revenue to generic erosion after the loss of exclusivity. The commercial impact depended on the number of approved ANDAs, the agreed launch dates, formulary substitution, generic discounting, and whether several manufacturers entered simultaneously.

For Forest and its successor commercial owners, the principal value of the case was delay. Every additional month before generic entry could preserve branded prescriptions and pricing. Once multiple generics entered, price erosion would typically accelerate because pharmacy benefit managers and wholesalers could substitute lower-cost vilazodone products.

The case did not involve a damages claim based on Accord's commercial sales because Accord had not launched the accused product during the ANDA dispute.

Key Takeaways

• Forest Laboratories v. Accord Healthcare, No. 1:16-cv-00375, was a Hatch-Waxman action involving generic vilazodone, marketed as Viibryd.
• Forest relied on Orange Book-listed patents covering vilazodone and related therapeutic or pharmaceutical subject matter.
• Viibryd's five-year FDA exclusivity had expired by the time of the 2016 litigation, but patent protection continued.
• The case ended without a reported trial judgment or published patent-invalidity decision.
• The commercial issue was the timing of Accord's potential generic launch.
• Viibryd faced generic, not biosimilar, competition.
• A settlement or dismissal in Accord's case did not necessarily resolve litigation against every other ANDA applicant.

FAQs About Forest Laboratories v. Accord Healthcare

Was Forest Laboratories v. Accord Healthcare a Paragraph IV case?

Yes. The action was an ANDA patent case arising from Accord's Paragraph IV certification concerning patents listed for Viibryd.

What was the Viibryd active ingredient?

Viibryd contains vilazodone hydrochloride, an antidepressant approved for major depressive disorder.

Did Accord launch generic Viibryd immediately after the lawsuit?

No public merits judgment in the case authorized immediate launch. Any launch timing depended on the case resolution, applicable patents, FDA approval, and the terms of any settlement.

Did the case invalidate Forest's Viibryd patents?

No reported decision in this action invalidated the asserted Viibryd patents. The case concluded without a published trial judgment resolving validity and infringement.

Could a generic manufacturer use a skinny label for vilazodone?

Potentially. A generic applicant may seek approval for permitted uses while carving out patented indications from its labeling. Whether that strategy avoids infringement depends on the patent claims, proposed label, product instructions, and inducement evidence.

References

1. U.S. District Court for the District of Delaware. (2016). Forest Laboratories, LLC v. Accord Healthcare, Inc., No. 1:16-cv-00375, docket filings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (2011). Viibryd (vilazodone hydrochloride) prescribing information. Forest Laboratories, Inc.

4. 21 U.S.C. § 355(j). Abbreviated new drug applications.

5. 35 U.S.C. § 271(e)(2). Patent infringement based on submission of an abbreviated new drug application.